Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04811573
Ignite Creation Date: 2024-05-06 @ 3:56 PM
Last Modification Date: 2024-10-26 @ 2:00 PM
Study NCT ID: NCT04811573
Protocol Section: NCT04811573
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food
Official Title: Bioequivalence of Three Different Tablet Formulations of 30 mg of Apremilast EU-sourced Otezla vs US-sourced Otezla vs Japan-sourced Otezla Administered in Healthy Male and Female Subjects in the Fasted State as Well as for EU-sourced Otezla vs US-sourced Otezla in the Fed State an Open-label Randomised Single-dose Five-period Ten-sequence Crossover Study
Acronym: None
Organization: Boehringer Ingelheim
Organization Class: INDUSTRY
Organization Study ID: 1407-0041
Secondary IDs
Secondary ID Type Domain Link
2019-005037-37 EUDRACT_NUMBER None None
Start Status Module Data
Status Verified Date: 2022-08
Overall Status: TERMINATED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Boehringer Ingelheim
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Boehringer Ingelheim
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload